114.28 +0.01 (0.01%)
After hours: 4:21PM EDT
|Bid||114.27 x 800|
|Ask||114.28 x 800|
|Day's Range||113.04 - 114.45|
|52 Week Range||78.90 - 114.45|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||39.96|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||0.66 (0.58%)|
|1y Target Est||110.09|
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
Zoetis Inc NYSE:ZTSView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ZTS totaled $5.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
In this daily bar chart of ZTS, below, we can see that prices just broke out on the upside. ZTS is above the rising 50-day moving average line after a number of tests of the line since the middle of April. The volume of trading doesn't seem to show much but the On-Balance-Volume (OBV) line rose with the price action from late January.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Wendys Co (NASDAQ: WEN ) is one of his absolute favorites. Cramer is a buyer of Zoetis Inc (NYSE: ZTS ). He added that the stock hit another ...
The best pharmaceutical stocks to buy have commonalities: strong Composite Ratings and Relative Strength Ratings.
Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Driven by ESG investing and built to thrive in a market correction, Calvert Equity is among the best mutual funds this year, topping the S&P by 50%.
Pharmaceuticals are a tricky business. Public policy, science, R&D;, global growth and regulation all play a role, sometimes outsize, in the success of pharmaceutical stocks.But some Big Pharma companies and a few other industry firms have managed these and other factors better than others. And along the way, they have built up a considerable "moat" - some sort of considerable competitive advantage - around profitable businesses. Some of these same companies are building bridges to further profitability via deep drug pipelines, innovative new treatments and transformative acquisitions.Here's a deeper look into five pharmaceutical stocks that have compelling moats, bridges or both. These advantages make them more likely to provide stable growth over the long term. SEE ALSO: The Best Health-Care Stocks to Buy for 2019
Zoetis Inc. (ZTS) will participate in the William Blair 39th Annual Growth Stock Conference on Thursday, June 6, 2019, in Chicago, Ill. Juan Ramón Alaix, Chief Executive Officer, will represent the company and respond to questions from analysts. Zoetis is the leading animal health company, dedicated to supporting its customers and their businesses. Building on more than 65 years of experience in animal health, Zoetis discovers, develops, manufactures and markets veterinary vaccines, medicines and diagnostics, which are complemented by genetic tests, biodevices and a range of services.
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Zoetis Inc. (ZTS) will participate in the Stifel 2019 Dental & Veterinary Conference on Wednesday, May 29, 2019, in New York, N.Y. Clint Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics will represent the company and respond to questions from analysts.
Zoetis held its annual meeting today in Short Hills, N.J., with Chairman Michael B. McCallister presiding over the business portion of the meeting and shareholder voting. Chief Executive Officer Juan Ramón Alaix discussed the company’s strong performance in 2018 and its strategies for continued growth and market leadership in the global animal health industry. Juan Ramón Alaix, Paul M. Bisaro, Frank A. D’Amelio and Michael B. McCallister have been elected as directors for three-year terms.
Teva stock toppled Thursday after the generic drug behemoth's first-quarter report "gave no reason for confidence," according to one analyst. Meanwhile, Zoetis stock moved into buy range.
Zoetis (ZTS) delivered earnings and revenue surprises of 11.39% and -0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Parsippany, New Jersey-based company said it had net income of 65 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, were 88 cents ...